The European Technology Platform Nanomedicine published its strategic research agenda in December 2006, before the first calls for proposals for the Seventh EU Framework Programme on RTD. About 20 researchers from Nano2Life were involved in the preparation of this paper.

The document outlines roadmaps for European nanotechnology research for diagnostics, targeted delivery and regenerative medicine for 1-2, 3-5 and more than 5 years. The strategic research agenda is focused at some major diseases which lead to substantial socio-economic impact in Europe: Cardiovascular diseases, Cancer, Muscoskeletal & Inflammatory diseases, Neurodegenerative diseases, Diabetes, Infectious diseases and enabling technologies. Apart from socio-economic impacts, also ethical, legal and social aspects are analysed in detail.